Sequist, L. V., Chiang, A., Gilbert, J., Gordon, M., Conkling, P. R., Thompson, D., … Gettinger, S. (2016). Clinical activity, safety and predictive biomarkers results from a phase Ia atezolizumab (atezo) trial in extensive-stage small cell lung cancer (ES-SCLC). In ANNALS OF ONCOLOGY (Vol. 27). OXFORD UNIV PRESS. https://doi.org/10.1093/annonc/mdw389.3

Sequist, L. V., A. Chiang, J. Gilbert, M. Gordon, P. R. Conkling, D. Thompson, J. P. Marcoux, et al. “Clinical activity, safety and predictive biomarkers results from a phase Ia atezolizumab (atezo) trial in extensive-stage small cell lung cancer (ES-SCLC).” In ANNALS OF ONCOLOGY, Vol. 27. OXFORD UNIV PRESS, 2016. https://doi.org/10.1093/annonc/mdw389.3.

Sequist LV, Chiang A, Gilbert J, Gordon M, Conkling PR, Thompson D, et al. Clinical activity, safety and predictive biomarkers results from a phase Ia atezolizumab (atezo) trial in extensive-stage small cell lung cancer (ES-SCLC). In: ANNALS OF ONCOLOGY. OXFORD UNIV PRESS; 2016.

Sequist, L. V., et al. “Clinical activity, safety and predictive biomarkers results from a phase Ia atezolizumab (atezo) trial in extensive-stage small cell lung cancer (ES-SCLC).” ANNALS OF ONCOLOGY, vol. 27, OXFORD UNIV PRESS, 2016. Wos, doi:10.1093/annonc/mdw389.3.

Sequist LV, Chiang A, Gilbert J, Gordon M, Conkling PR, Thompson D, Marcoux JP, Antonia SJ, Liu B, Shames DS, Lopez-Chavez A, O’Hear C, Fasso M, Gettinger S. Clinical activity, safety and predictive biomarkers results from a phase Ia atezolizumab (atezo) trial in extensive-stage small cell lung cancer (ES-SCLC). ANNALS OF ONCOLOGY. OXFORD UNIV PRESS; 2016.